AN2 Therapeutics | Investor Presentation Deck | 25 slides

AN2 Therapeutics · 2022-08
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON

Slide inventory

25
every slide · same image gating as the playbook
01
Slide 1
The slide uses a global map background and patient portraits to emphasize the scope and human impact of the company's mission.inspire_vision
03
front_matter
04
The slide uses a grid layout to display headshots, names, titles, and company logos for both management and board members.other
05
The slide uses a split-layout with company mission on the left and product details on the right.summarize
06
The slide uses a Gantt-style visualization for clinical trial progress.plan_implementation
07
transition
08
frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
09
Uses a nested Venn/funnel diagram to illustrate market segmentation.size_opportunity
Open slide detailBeat · ProblemLoop · Cost Of Inaction
10
The slide uses a two-part table structure to contrast standard care with refractory care, emphasizing toxicity and lack of FDA approval for many agents.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
11
The slide presents a balanced view, showing both efficacy and significant safety/tolerability concerns for the competitor drug.compare_peers
12
Scientific illustration showing molecular binding interaction.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
13
EBO = Epetraborole; MAC = Mycobacterium avium complex; MIC = Minimum Inhibitory Concentration.compare_peers
Open slide detailBeat · SolutionLoop · Golden Circle
14
The chart demonstrates dose-dependent efficacy of Epetraborole (EBO) against M. avium 2285 (R).show_traction
Open slide detailBeat · SolutionLoop · Golden Circle
15
The charts demonstrate dose-dependent efficacy and synergy between EBO and SoC.show_traction
Open slide detailBeat · Traction
16
Includes a timeline diagram of the study design and bulleted clinical outcomes.show_traction
Open slide detailBeat · Traction
17
The slide highlights the therapeutic potential of the drug by showing superior accumulation at the site of infection.analyze_data
Open slide detailBeat · Traction
18
The slide outlines a seamless transition between Phase 2 and Phase 3 trials for a specific drug candidate.plan_implementation
19
Uses a funnel-like diagram to represent market segments.size_opportunity
Open slide detailBeat · Business Model
20
The table uses checkmarks and X marks to denote performance against specific clinical criteria.compare_peers
Open slide detailBeat · Business Model
21
QIDP = Qualified Infectious Disease Product Designationother
Open slide detailBeat · Business Model
22
The timeline shows clinical trial phases (Chronic Tox, Phase 1b, Ph 2/3 TR-MAC, Ph 1 Japan, Ph 2/3 Topline Data).plan_implementation
Open slide detailBeat · Business Model
23
inspire_vision
24
The slide uses a split-layout with a company mission statement on the left and product-specific details on the right.summarize
25
The slide uses a global map background and patient portraits to emphasize the scope and human impact of the company's mission.inspire_vision